Expanding the biopharmaceutical industry's involvement in fighting neglected diseases

Health Affairs

Volumn 28, Issue 6, 2009, Pages 1774-1777

  Geraghty, James A ^a  

^a Gensyme Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DISEASE CONTROL; DRUG INDUSTRY; DRUG RESEARCH; HEALTH CARE POLICY; HEALTH SERVICE; MEDICAL RESEARCH;

BIOPHARMACEUTICS; COMMUNICABLE DISEASE CONTROL; DRUG INDUSTRY; HEALTH POLICY; HUMANS; NEGLECTED DISEASES; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; UNITED STATES;

EID: 77952119855     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.6.1774     Document Type: Conference Paper

References (13)

1. Food and Drug Administration Amendments Act of 2007,1102 (Codified at 21 U.S.Code 524)
2. Iglehart JK. Global health care matters: broadening THe focus. Heakh Aff (Millwood). 2007;26 (4):918-9.
3. Wellcome Trust and London School of Economics and Political Science. The new landscape of neglected disease drug development. London (UK): Wellcome Trust; 2005.
4. Dunavan CP. Awakening to global health. Health Aff (Millwood). 2007;26(4):1135-40.
5. Hotez P, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, et aL Control of neglected tropical diseases. N Eng J Med. 2007;357(10): 1018-27.
6. Moran M, Guzman J, Ropars AL, McDonald A, Jameson N, Omune B, et al. Neglected disease research and development: how much are we really spending? PLoS Medicine. 2009;6(2):e30.
7. Bio Ventures for Global Health. Closing the global heakh innovation gap: a role for the biotechnology industry in drug discovery for neglected diseases. Washington (DC): BVGH; 2007.
8. Gilden D. Genzyme, the Broad Institute of Harvard and MIT, and the Medicines for Malaria Venture (MMV) collaborate in a unique public/private partnership aimed at eradicating malaria. Case Studies for Global Health. Deerfield (IL): Global Health Case Studies Initiative; 2009.
9. Shimmings A. 2008 Scrip awards celebrate industry's achievements. London (UK): Scrip; 2008 Dec 11.
10. Porter M, Kramer M. The competitive advantage of corporate philanthropy. Harvard Bus Rev. 2002;80(12):57-68.
11. Kanter RM. From spare change to real change: the social sector as beta site for business innovation. Harvard Bus Rev. 1999;77(3):122-33.
12. Institute of Medicine. The US commitment to global heakh: recommendations for the new administration. Washington (DC): IOM; 2009.
13. Anderson GF. Spurring new research for neglected diseases, Heakh Aff (Millwood). 2009; 28(6):1750-59.